Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarantus Bioscience Holdings Inc Announces Positive Orphan Data For MANF In Retinitis Pigmentosa

Monday, 12 Aug 2013 09:21am EDT 

Amarantus Bioscience Holdings Inc announced positive data for MANF in the degenerative disease known as Retinitis Pigmentosa. The study concluded that Intravitreal injection of recombinant human MANF protein protects both rods and cones from retinal degeneration in an animal model of RP. RP is a degenerative disorder of the eye that affects roughly 100,000 people in the United States, meaning that it qualifies as an orphan disease under FDA guidelines. RP refers to a group of inherited diseases causing retinal degeneration. The cell-rich retina lines the back inside wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision as well as the degeneration in color perception and central vision; night blindness is one of the earliest and most frequent symptoms of RP. RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually. 

Company Quote